1. Home
  2. DBVT vs MCS Comparison

DBVT vs MCS Comparison

Compare DBVT & MCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DBV Technologies S.A.

DBVT

DBV Technologies S.A.

HOLD

Current Price

$8.92

Market Cap

850.9M

Sector

Health Care

ML Signal

HOLD

Logo Marcus Corporation (The)

MCS

Marcus Corporation (The)

SELL

Current Price

$28.12

Market Cap

873.2M

ML Signal

SELL

Company Overview

Basic Information
Metric
DBVT
MCS
Founded
2002
1935
Country
France
United States
Employees
90
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
850.9M
873.2M
IPO Year
2014
1994

Fundamental Metrics

Financial Performance
Metric
DBVT
MCS
Price
$8.92
$28.12
Analyst Decision
Buy
Buy
Analyst Count
7
5
Target Price
★ $38.55
$32.25
AVG Volume (30 Days)
★ 338.0K
188.9K
Earning Date
10-28-2026
10-30-2026
Dividend Yield
N/A
★ 1.27%
EPS Growth
★ 10.26
N/A
EPS
N/A
★ 0.77
Revenue
$5,636,000.00
★ $758,458,000.00
Revenue This Year
N/A
$14.64
Revenue Next Year
$1,630.16
$2.22
P/E Ratio
★ N/A
$36.79
Revenue Growth
★ 35.77
3.11
52 Week Low
$8.86
$12.85
52 Week High
$26.19
$32.42

Technical Indicators

Market Signals
Indicator
DBVT
MCS
Relative Strength Index (RSI) 23.59 55.90
Support Level N/A $28.19
Resistance Level $14.90 $28.89
Average True Range (ATR) 0.47 0.77
MACD -0.14 0.09
Stochastic Oscillator 0.12 75.44

Price Performance

Historical Comparison
DBVT
MCS

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

About MCS Marcus Corporation (The)

Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.

Share on Social Networks: